✦ LIBER ✦

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

✍ Scribed by M Hallek; K Fischer; G Fingerle-Rowson; AM Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; PL Zinzani; F Caligaris-Cappio; JF Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; CM Wendtner; BF Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer

Book ID: 117307281
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 309 KB
Volume: 376
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(10)61381-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fludarabine plus alemtuzumab versus flud

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

✍ Thomas Elter; Liana Gercheva-Kyuchukova; Halyna Pylylpenko; Tadesuz Robak; Brani 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 286 KB

A randomized phase II trial of fludarabi

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

✍ Peter Hillmen; Dena R. Cohen; Kim Cocks; Andrew Pettitt; Hazem A. Sayala; Andy C 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

The Addition of Rituximab to Fludarabine

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia

✍ Amit Mahipal; Mark Weiss 📂 Article 📅 2010 🏛 Current Science Inc. 🌐 English ⚖ 80 KB

PCN103 PHARMACOECONOMIC ANALYSIS OF THE

PCN103 PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FLUDARABINE-CYCLOPHOSPHAMIDE REGIMEN IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS IN SPAIN

✍ F Bosch; LF Casado; JA Garcia-Marco; F Gilsanz; M Gonzalez Diaz; C Rayon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

5.40 Rituximab Maintenance in Patients w

5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC)

✍ Francesc Bosch; Pau Abrisqueta; Neus Villamor; María José Terol; Eva González-Ba 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 250 KB

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO